Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicentre study of nomacopan in paediatric haematopoietic thrombotic microangiopathy
2020-000086-17Phase 3Unknown
- Sponsor
- Akari Therapeutics
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nomacopan in thrombotic microangiopathies (TMA), sponsored by Akari Therapeutics. Primary endpoint: Composite Primary Endpoint. Status: unknown.
02
Drugs
nomacopan
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on 2020-000086-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000086-17.